Literature DB >> 391094

A double blind controlled trial of N-(3',4'-dimethoxycinnamoyl) anthranilic acid on children with bronchial asthma. N-5' Study Group in Children.

H Shioda.   

Abstract

A double blind controlled trial of N-(3',4'-dimethoxycinnamoyl) anthranilic acid (N-5') was carried out for treating children with bronchial asthma to determine its efficacy and safety. The results showed that the drug was significantly more effective in the N10 and N5 groups than in the N0 group. Adverse reactions appeared only in one patient in the N10 group who complained of slight anorexia while another patient in the N0 group reported moderate diarrhoea. Moreover there was no indication of abnormality in further laboratory investigations. It can be therefore concluded that this drug is useful for the treatment of children with bronchial asthma.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 391094     DOI: 10.1111/j.1398-9995.1979.tb01701.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  3 in total

Review 1.  The Atrium in Atrial Fibrillation - A Clinical Review on How to Manage Atrial Fibrotic Substrates.

Authors:  Pedro Silva Cunha; Sérgio Laranjo; Jordi Heijman; Mário Martins Oliveira
Journal:  Front Cardiovasc Med       Date:  2022-07-04

2.  Tranilast Blocks the Interaction between the Protein S100A11 and Receptor for Advanced Glycation End Products (RAGE) V Domain and Inhibits Cell Proliferation.

Authors:  Yen-Kai Huang; Ruey-Hwang Chou; Chin Yu
Journal:  J Biol Chem       Date:  2016-05-12       Impact factor: 5.157

3.  Utility of a novel turn-off fluorescence probe for the determination of tranilast, an adjunctive drug for patients with severe COVID-19.

Authors:  Diaa Dagher; Heba Elmansi; Jenny Jeehan Nasr; Nahed El-Enany
Journal:  RSC Adv       Date:  2022-08-09       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.